AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
adipiodone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| radiopharmaceuticals, iodine-contained | 1455 | 606-17-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A water-soluble radiographic contrast media for cholecystography and intravenous cholangiography.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,GRK3,GSK3B,IKBKB,ITK,JAK1,JAK2,JAK3,KDR,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAPK1,MAPK10,MAPK12,MAPK7,MAPK8,MAPK9,MAPKAPK2,MAPKAPK5,MARK4,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM1,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 | 67 | |||
| kinase-selectivity-class | ACVR2A,ACVR2B,AURKA,AURKB,AURKC,AXL,BRAF,CAMK2B,CAMK2D,CDK16,CDK4,CDK9,CLK4,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FGFR1,GRK2,GSK3A,GSK3B,JAK2,MAP2K4,MAP2K6,MAP3K14,MAP3K21,MAP4K1,MAPK1,MAPK12,MAPK7,MAPK8,MARK4,MET,PDK1,PDK4,PIK3CB,PIK3CD,PIK3CG,PIM3,PRKAA1,PRKDC,SIK2,STK10,STK33,SYK,TEK,TGFBR1,TTK,UHMK1,ULK1,ZAP70 | 52 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 27, 1954 | FDA | BRACCO |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Blepharospasm | 38.94 | 21.98 | 19 | 1537 | 55426 | 90571465 |
| Epilepsy | 31.91 | 21.98 | 19 | 1537 | 82187 | 90544704 |
| Breast cancer stage III | 31.44 | 21.98 | 19 | 1537 | 84428 | 90542463 |
| Hypercholesterolaemia | 30.77 | 21.98 | 20 | 1536 | 100872 | 90526019 |
| Back injury | 24.09 | 21.98 | 13 | 1543 | 46609 | 90580282 |
| Facet joint syndrome | 24.02 | 21.98 | 17 | 1539 | 98372 | 90528519 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Blepharospasm | 41.58 | 31.64 | 18 | 1367 | 54833 | 110533081 |
| Hypercholesterolaemia | 35.75 | 31.64 | 19 | 1366 | 90818 | 110497096 |
| Breast cancer stage III | 35.29 | 31.64 | 18 | 1367 | 79099 | 110508815 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | V08AC04 | VARIOUS CONTRAST MEDIA X-RAY CONTRAST MEDIA, IODINATED Watersoluble, hepatotropic X-ray contrast media |
| FDA MoA | N0000010258 | X-Ray Contrast Activity |
| MeSH PA | D003287 | Contrast Media |
| MeSH PA | D064907 | Diagnostic Uses of Chemicals |
| FDA EPC | N0000180185 | Radiographic Contrast Agent |
| CHEBI has role | CHEBI:37338 | radioopaque medium |
Related Drugs by ATC class:
V08AC Watersoluble, hepatotropic X-ray contrast media 8 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.03 | acidic |
| pKa2 | 3.64 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| N0000007781 | NUI |
| D01774 | KEGG_DRUG |
| 4017611 | VANDF |
| C0021971 | UMLSCUI |
| CHEBI:31176 | CHEBI |
| IDB | PDB_CHEM_ID |
| CHEMBL1165268 | ChEMBL_ID |
| DB04711 | DRUGBANK_ID |
| 3739 | PUBCHEM_CID |
| 29456 | RXNORM |
| 301 | MMSL |
| 4901 | MMSL |
| d01454 | MMSL |
| 001222 | NDDF |
| 001230 | NDDF |
| 398939009 | SNOMEDCT_US |
| 73212002 | SNOMEDCT_US |
| D007458 | MESH_DESCRIPTOR_UI |
| CHEMBL3989806 | ChEMBL_ID |
| CHEMBL1200350 | ChEMBL_ID |
| 3521-84-4 | SECONDARY_CAS_RN |
| 2618-26-0 | SECONDARY_CAS_RN |
| 7400 | IUPHAR_LIGAND_ID |
| 313 | INN_ID |
| C006753 | MESH_SUPPLEMENTAL_RECORD_UI |
| TKQ858A3VW | UNII |
| TKQ858A3VW | INXIGHT DRUGS |
Pharmaceutical products:
None